Dr Sharareh Eskandari is a mid-career postdoctoral researcher at the Institute for Biomedicine and Glycomics, with over 8 years of experience in translational research focused on vaccine development against infectious diseases. She has made significant contributions to the development of vaccines for Group A Streptococcus, COVID-19, and gonorrhoea in preclinical / clinical trial stage. Dr. Eskandari possesses expertise in the preclinical development of therapeutics, including lipid nanoparticle formulations, physicochemical characterization, pharmacology, and pharmacodynamic studies. She is also skilled in developing molecular and cell-based assays for immunological assessment of serum antibodies and cytokines, such as enzyme-linked immunosorbent assay (ELISA), serum bactericidal activity assay, and various cell-based assays. Her work is evidenced by 21 publications, which have collectively received 1046 citations (h-index: 13, i10-index: 15 as of Feb 2026). She is the first author on 5 research papers and has also contributed to 2 book chapters and 2 review articles as the first author. Dr Eskandari has a PharmD (1999: Tehran University of Medical Sciences) and PhD in medicinal chemistry and molecular biosciences for vaccine development (2016: University of Queensland). Her past work experience in the pharmaceutical industry has fortified her expertise in formulation and characterisation, in-vitro, in-vivo, and stability assays, data management and statistical data analysis.